Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: D.B. Cooper who wrote (12801)	4/4/2004 1:48:54 PM
From: Boplicity	Read Replies (2) \| Respond to of 13815

Don, anyone, I bet ya sig knows this. I how to join copper and steel. I want to attach a copper tube to a piece of steel. Greg

To: D.B. Cooper who wrote (12801)	4/4/2004 4:21:30 PM
From: Pedro Joaristi	Respond to of 13815

No Don, I don't follow that one. I mainly follow the BIOS that are the leaders in monoclonal antibody research. I believe that, arguably, this is the most promising cancer treatment in the pipeline. Monoclonal antibodies "cling" to markers in the tumor cells and are a way to deliver treatment straight to the source. In 1998 my mother was diagnosed with one of the rarest and invariably fatal types of Non-Hodgkins Lymphoma- Mantle Cell. She was one of the first patients to be infused with the first monoclonal antibody therapy approved by the FDA- Rituzan (also known as Rituximab and Mabthera). The research leaders in this field are BIIB (Biogen + Idec), Genentech and CRXA. BIIB has a new and improved Rituxan in the market called Zevalin (ibritumomab tiuxetan), which contains a radioctive isotope that is delivered straight to the tumor cells. Pedro